Advocates, experts cry foul over Amylyx's new ALS drug, citing issues with price, PhIII commitment
Not 24 hours after earning the first ALS drug approval in five years, Amylyx Pharmaceuticals’ Relyvrio is already drawing scrutiny. And it’s coming from multiple fronts.
In an investor call Friday morning, Amylyx revealed that it would charge about $158,000 per year, a price point that immediately drew backlash from ALS advocates and some outside observers. The cost reveal had been highly anticipated in the immediate hours after Thursday evening’s approval, though Amylyx only teased Relyvrio would cost less than previously approved drugs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.